Delivery Order SPE2DB20D9329-SPE2DB26FZH86
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,083.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Lucentis 0.5 mg/0.05 mL syringes. This firm fixed-price delivery order, issued on October 29, 2025, with an ultimate completion date of November 20, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,345.48 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lucentis 0.5 mg/0.05 mL. This delivery order, issued without a set-aside designation, is scheduled for completion by November 21, 2025, and represents a routine pharmaceutical procurement to support Department of Defense medical supply needs. DMS Pharmaceutical Group...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,544.44, is for the delivery of Lucentis 0.5 mg/0.05 ml syringes to support the medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued up to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,633.32 contract is for the delivery of Lucentis 0.5 mg/0.05 ml, a prescription medication, to support the medical supply needs of military health facilities. This delivery order is part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the...
- This firm-fixed-price delivery order, valued at $3,035.76, was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This single-award IDC allows the DLA to issue delivery orders for a comprehensive range of...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,088.88 contract will provide LUCENTIS 0.5 MG/0.05 ML SYRING 0.05ML medical supplies to support the recurring pharmaceutical needs of military health facilities under the DLA's Medical Supply Chain division. This delivery order is part of a larger $499,999,999 indefinite delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on April 28, 2025, for Lucentis 0.3 mg/0.05 ml syringes. The contract carries a ceiling value of $1,937.40 under a firm fixed-price delivery order structure with an ultimate completion date of May 19, 2025. This award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete on its...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,861.10, is for the delivery of LUCENTIS 0.5 MG/0.05 ML SYRING 0.05ML, a pharmaceutical product. The contract is a firm fixed-price delivery order with a performance period through May 29, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the...
- This contract was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is a delivery order under a larger indefinite delivery contract (IDC) valued up to $499,999,999 that runs through December 31, 2025. This IDC, known as the SPE2DB program, allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $1,544.44, is for the supply of the pharmaceutical product Lucentis 0.5 mg/0.05 ml syringe 0.05 ml. DMS Pharmaceutical Group holds a significant single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
- SPE2DB20D9329Indefinite Delivery Contract
- SPE2DB20D9329-SPE2DB26FZH86Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,639.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lucentis 0.5 mg/0.05 ml syringes. This firm fixed-price delivery order, issued on November 12, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The order fulfills immediate pharmaceutical supply requirements for Department of Defense military healthcare operations. This delivery order is issued under DMS Pharmaceutical Group's newly awarded Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated SPE2DR. The parent IDC, awarded on November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. As one of multiple regional prime vendor contractors within the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group is positioned to serve as a critical supplier of branded and generic pharmaceuticals, biologics, and medical consumables to support recurring medical supply needs across Department of Defense healthcare facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 11/12/25 |